4SC discovers and develops targeted small-molecule drugs for the treatment of diseases with a high unmet medical need in various autoimmune and cancer indications. These drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. At the end of September 2014, 4SC Group had 65 employees. The company was founded in 1997. 4SC AG (VSC) has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.